Xing'er Christine Koo

Title: Innovations of Xing'er Christine Koo

Introduction

Xing'er Christine Koo is a notable inventor based in Singapore, recognized for her contributions to the field of biotechnology. With a total of six patents to her name, she has made significant strides in developing innovative solutions for medical challenges.

Latest Patents

One of her latest patents is focused on cross-species anti-latent TGF-beta 1 antibodies and methods of use. The objective of this invention is to provide antibodies that inhibit a protease-mediated activation of latent TGF-beta 1 without affecting integrin-mediated activation. This innovation has the potential to enhance therapeutic strategies in various medical applications. Another significant patent involves anti-dengue virus antibodies and polypeptides containing variant Fc regions. This disclosure provides methods for making and using these antibodies, which are crucial for treating dengue virus infections. The polypeptides described in this patent have applications in treating viral infections, showcasing her commitment to addressing pressing health issues.

Career Highlights

Throughout her career, Xing'er Christine Koo has worked with prominent organizations such as Chugai Seiyaku Kabushiki Kaisha and the Agency for Science, Technology and Research. Her experience in these institutions has contributed to her expertise and innovative capabilities in the field.

Collaborations

Xing'er has collaborated with notable colleagues, including Katja Fink and Roland Zuest. These partnerships have likely fostered a creative environment that encourages the development of groundbreaking inventions.

Conclusion

Xing'er Christine Koo's work exemplifies the spirit of innovation in biotechnology. Her patents reflect a dedication to advancing medical science and improving patient outcomes. Her contributions are invaluable to the ongoing fight against diseases and the development of new therapeutic methods.